Spark Therapeutics Inc. (ONCE)

45.08
NASDAQ : Health Technology
Prev Close 43.89
Day Low/High 43.52 / 45.93
52 Wk Low/High 34.53 / 96.59
Avg Volume 588.40K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.63B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options

Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options

Investors considering a purchase of Spark Therapeutics Inc shares, but tentative about paying the going market price of $23.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $20 strike, which has a bid at the time of this writing of $3.50.

Relative Strength Alert For Spark Therapeutics

Relative Strength Alert For Spark Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd

Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd

While the world's attention turns to Pennsylvania on February 2 nd for Groundhog Day prognostications about continuing winter weather, investment professionals will gather in Philadelphia on February 3 rd for the 2016...

WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum

WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum

Join Emerald Asset Management for the 23 rd annual Groundhog Day Investment Forum on February 3 rd in Philadelphia.

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

My biotech and pharma superlatives for 2015.

Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering

Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering

The Children's Hospital of Philadelphia Foundation to be a Selling Stockholder

Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting

Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting

Presentation Highlights Positive Trend in Visual Acuity, Together With Highly Statistically Significant Positive Results in Primary and First Two Secondary Efficacy Endpoints

Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease

Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease

Preclinical Data Published in Science Translational Medicine Demonstrate Delay in Onset and Progression of a Form of Batten Disease

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak

Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak

Apple (AAPL) shares bucked the upward trend in tech stocks after Citigroup analysts cut iPhone sales estimates on Monday.

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

The shares of Spark Therapeutics are surging after the company announced that its lead gene therapy product candidate had met its primary endpoint in a Phase 3 trial.

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

Cramer says to wait on Johnson Controls and avoid Jacobs Engineering.

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Cramer says these five groups must be approached with caution.

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

Biotech columnist Adam Feuerstein answers readers' questions about health care.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.

TheStreet Quant Rating: D (Sell)